Ligand Posts $1.43 Per-Share Q3 Loss as Royalty Story Faces First Test
LGND sits 77% above its 52-week low of $175.89.
Summary
Ligand reported a third-quarter loss of $1.43 per share, or $28.5M, a sharp swing from the profitable second quarter when net income hit $48.5M on $63.7M of revenue, while adjusted earnings came in at $2.67 per share. The loss lands just weeks after the company closed its XOMA Royalty acquisition, which the September 8-K/A showed carried a $41.2M first-half loss of its own, so the red ink likely reflects deal-related and non-cash items rather than a collapse in the royalty base. The stock trades near its 52-week high at $311.87, so expectations were high and any sign of royalty deceleration will be punished. The headline gives only the per-share loss and adjusted EPS — no revenue, royalty growth, or guidance — so the full read depends on the release details and call. Watch whether Ligand reaffirms the raised full-year royalty outlook it issued with Q2; that is the number that matters for the thesis.
At the time of this announcement, LGND was trading at $311.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.4B. The 52-week trading range was $175.89 to $326.63. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.